Meanwhile, the genetic variants proxy lifelong HMGCR inhibition, which may not perfectly mimic the effect of mid-to-late life pharmacological statin use in terms of effect size, duration, or biological pathway; Lastly, the mechanisms by which statins use alleviated risk of PCa required further investigation. The gene discussed is HMGCR; the disease is posterior cortical atrophy.